Volume 26, Number 1—January 2020
Dispatch
Effect of Pediatric Influenza Vaccination on Antibiotic Resistance, England and Wales
Table 1
Projected effect of pediatric LAIV on antibiotic prescription rates, England and Wales*
| Age group | Influenza-attributed consultation rate† | Prescriptions per consultation | Direct prescribing rate reduction, unmatched‡ | Direct prescribing rate reduction, matched‡ | Overall LAIV effectiveness§ | Overall prescribing rate reduction¶ |
|---|---|---|---|---|---|---|
| 0–6 mo | 29.7 (23.7–35.9) | 0.597 (0.474–0.719) | – | – | 0.574 (0.501–0.651) | 10.2 (7.03–13.5) |
| 6 m–4 y | 29.7 (23.7–35.9) | 0.597 (0.474–0.719) | 7.46 (5.31–9.64) | 12.4 (8.85–16.1) | 0.663 (0.618–0.714) | 11.8 (8.31–15.4) |
| 5–14 y | 22.1 (17.6–26.7) | 0.588 (0.466–0.708) | 5.46 (3.89–7.06) | 9.11 (6.48–11.8) | 0.754 (0.709–0.794) | 9.81 (6.97–12.8) |
| 15–44 y | 12.8 (10.2–15.4) | 0.676 (0.536–0.814) | 3.64 (2.59–4.70) | 6.06 (4.31–7.83) | 0.446 (0.394–0.502) | 3.86 (2.66–5.09) |
| 45–64 y | 12.4 (9.84–14.9) | 0.805 (0.639–0.970) | – | – | 0.423 (0.374–0.484) | 4.22 (2.90–5.58) |
| >65 y |
12.2 (9.67–14.7) |
0.857 (0.680–1.03) |
– |
– |
0.477 (0.397–0.561) |
4.97 (3.34–6.68) |
| Overall | 14.7 (11.7–17.7) | 0.726 (0.576–0.875) | 5.80 (4.13–7.49) | 9.86 (7.01–12.9) | 0.494 (0.446–0.549) | 5.32 (3.74–7.00) |
*All estimates reported as mean (95% highest density interval). LAIV, live attenuated influenza vaccine; –, age group not subject to pediatric LAIV.
†Per 1,000 person-years in England and Wales.
‡Reduction in antibiotic prescriptions among vaccinees per 1,000 vaccine recipients, not accounting for herd immunity, presented separately for unmatched and matched seasons.
§Reduction in influenza cases assuming a 50% uptake among children 2–16 years of age, accounting for herd immunity.
¶Per 1,000 person-years in England and Wales, accounting for herd immunity.
1These authors contributed equally to this article.
Page created: December 18, 2019
Page updated: December 18, 2019
Page reviewed: December 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.